Promising COVID-19 Rapid Test Technology Enters Phase 1 of NIH Challenge

A promising new COVID-19 rapid-testing technology platform developed by Rover Diagnostics and Columbia Engineering has been selected by the NIH to enter Phase 1 of the RADx initiative to support new COVID-19 testing technologies. The affordable, portable, and ultrafast point-of-care Rover platform provides reverse transcription polymerase chain reaction results in eight minutes, faster than any other test of its kind, with targeted accuracy to match laboratory-based tests.